Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Siobhán Mulhern-Haughey

Biographic Data

ID7652218
NAMESiobhán Mulhern-Haughey
GIVEN NAMESSiobhán
FAMILY NAMEMulhern-Haughey
SIGNATUREMULHERN-HAUGHEY S
AFFILIATIONSJanssen (Ireland)
ORCID0000-0002-9708-4356
VERIFIEDYes
TOTAL WORKS2
TOTAL CITATIONS0
AUTHOR COUNT2
EDITOR COUNT0
FIRST PUBLICATION YEAR2023
LATEST PUBLICATION YEAR2024
H-INDEX0
  • Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

    Open Access•Albino J Oliveira-Maia, Benoît Rive et al.•ARTICLE•Frontiers in Psychiatry•2024

    For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery

  • Iceberg study

    Open Access•Albino J Oliveira-Maia, Joachim Morrens et al.•ARTICLE•Frontiers in Psychiatry•2023

    ICEBERG supports that, at 6 months, esketamine NS has a substantial and significant benefit over RWT for patients with TRD. While results may be affected by unobserved confounding factors, threshold analyses suggested these were unlikely to impact the study conclusions.To view an animated summary of this publication, please click on the Supplementary video

No prominent works on this page.

  • Iceberg study

    Open Access•Albino J Oliveira-Maia, Joachim Morrens et al.•ARTICLE•Frontiers in Psychiatry•2023

    ICEBERG supports that, at 6 months, esketamine NS has a substantial and significant benefit over RWT for patients with TRD. While results may be affected by unobserved confounding factors, threshold analyses suggested these were unlikely to impact the study conclusions.To view an animated summary of this publication, please click on the Supplementary video

  • Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission

    Open Access•Albino J Oliveira-Maia, Benoît Rive et al.•ARTICLE•Frontiers in Psychiatry•2024

    For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery

Anesthesia (2 works) · Medicine (2 works) · Nasal administration (2 works) · Nasal spray (2 works) · Pharmacology (2 works) · Treatment of Major Depression (2 works) · Confidence interval (1 works) · Depression (economics (1 works) · Geology (1 works) · Ginkgo biloba and Cashew Applications (1 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae